CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today announced that the Nominating and Corporate Governance Committee of its board of directors has nominated Dennis M. Fenton, Ph.D., for election to the board. Mr. Fenton was executive vice president of operations at Amgen when he retired from the company in 2008. The nomination fulfills the commitment made by Genzyme as part of the agreement announced in April with Relational Investors, LLC to nominate an independent director recommended by Relational with substantial expertise in biopharmaceutical manufacturing and operations.
